clinical trial · NCT06491563
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
For Treatment of Chronic Hepatitis B Virus InfectionBRII-179BRII-835 (VIR-2218)PEG-IFNα
brief summary
This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.
started
Aug 6, 2024
primary completion
Dec 1, 2026
completion
Jun 1, 2027
last updated
Dec 30, 2024
official title
A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol